HealthTech180
  • Home
  • Activities
  • Our Team
  • Contact Us
Select Page

Azeria Therapeutics Announces £32.0 Million Series B Financing

by admin | Nov 25, 2019 | Funding

 Azeria Therapeutics, a newly formed pioneer factor drug discovery company, announced a £32 million Series B financing in which Syncona has committed £29.5 million alongside existing investor the CRT Pioneer Fund. Azeria was originally founded in 2017 by Sixth Element...

Shape Therapeutics raises $35.5M Series A round to develop RNA-based gene editing technology

by admin | Nov 11, 2019 | Funding

A company developing a means to edit RNA has raised more than $30 million in a venture capital funding round. Seattle-based Shape Therapeutics, or ShapeTx, said that it had raised a $35.5 million Series A financing, led by New Enterprise Associates and with...

ADC Therapeutics enters licence option deal with Avacta Group

by admin | Oct 21, 2019 | Licensing

ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates. Under the terms of the agreement, Avacta Group (Cambridge, UK) will provide three small Affimer proteins designed to bind to...
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.

Categories

Follow Us

Tags

AI Alzheimer antibodies Azitra Bioeq Biosimilar Cancer cardiovascular cell therapy CE Mark clinical trial Diagnostics Digital Health Distribution Drug Discovery Enterome EpiVax' FDA FDA approval funding fundraising HIV Immunogenicity Immunotherapies Licensing M&A medical device microbiome Neuro next-gen sequencing PathAI pathology Pepticom pharma RNA robots Shape Therapeutics skin software SurgiMab Therapeutics therapies USA VIrology Virus

Home
Activities
Our Team
Contact Us

 contact@healthtech180.com

Privacy Policy

© 2022 HealthTech180 Advisory S.L.